Hematologic Malignancy
Lymphoid Neoplasm
CI-CAN-00009335Explore in graph →
Hematologic2,419 active trials60 approved drugs271 evidence items
- OncoTree
- LNM
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00009335Explore in graph →
Clinical trials
8,886 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,374)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01416428 | Open-label Study of the Safety and Activity of Oprozomib in Patients With Hematologic Malignancies | terminated | Phase 1 / Phase 2 | 210 | AmgenINDUSTRY | 1 | Nov 8, 2022 | clinicaltrials |
| NCT03518112 | Low-Intensity Chemotherapy and Blinatumomab in Treating Patients With Philadelphia Chromosome Negative Relapsed or Refractory Acute Lymphoblastic Leukemia | terminated | Phase 2 | 6 | M.D. Anderson Cancer CenterOTHER | 1 | Nov 4, 2022 | clinicaltrials |
| NCT04504708 | Dose-Escalation and Dose-Expansion Study of ZX-101A in Patients With Relapsed/Resistant or Refractory Advanced Hematologic Malignancies | terminated | Phase 1 / Phase 2 | 6 | Hangzhou Zenshine Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Oct 21, 2022 | clinicaltrials |
| NCT04444141 | A Study of PD-1/CTLA-4 Bispecific AK104 in Relapsed or Refractory Peripheral T-cell Lymphoma | terminated | Phase 1 / Phase 2 | 6 | AkesoINDUSTRY | 1 | Oct 19, 2022 | clinicaltrials |
| NCT02225275 | Lenalidomide and Obinutuzumab in Treating Patients With Recurrent or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | terminated | Phase 2 | 9 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 28, 2022 | clinicaltrials |
| NCT02531308 | Metformin in Combination With Standard Induction Therapy for Large B-cell Lymphoma (DLBCL)(DLBCL) | terminated | Phase 2 | 5 | Rush University Medical CenterOTHER | 1 | Sep 28, 2022 | clinicaltrials |
| NCT02572453 | Phase 2 Study of AT13387 (Onalespib) in ALK+ ALCL, MCL, and BCL-6+ DLBCL | terminated | Phase 2 | 25 | National Cancer Institute (NCI)NIH | 1 | Sep 13, 2022 | clinicaltrials |
| NCT03379051 | Phase I/II Study of Venetoclax or Lenalidomide in Combination With Ublituximab and Umbralisib in Subjects With Relapsed or Refractory CLL/SLL and NHL | terminated | Phase 1 / Phase 2 | 78 | TG Therapeutics, Inc.INDUSTRY | 1 | Aug 22, 2022 | clinicaltrials |
| NCT03422523 | Atezolizumab, Rituximab, Gemcitabine and Oxaliplatin in Patients With Relapsed or Refractory DLBCL Not Suitable for High-dose Therapy(ARGO) | terminated | Phase 2 | 53 | University Hospital Southampton NHS Foundation TrustOTHER | 1 | Aug 22, 2022 | clinicaltrials |
| NCT02361346 | Safety, PD & Efficacy of MT-3724 for the Treatment of Patients With Relapsed or Refractory DLBCL(MT-3724NHL001) | terminated | Phase 1 / Phase 2 | 38 | Molecular Templates, Inc.INDUSTRY | 10 | Aug 18, 2022 | clinicaltrials |
| NCT03488251 | PK,PD,Safety and Tolerability of Multiple Dose Regimens of MT-3724 With Gemcitabine and Oxaliplatin for the Treatment of Patients With Relapsed/Refractory Diffuse Large B Cell Non-Hodgkin's Lymphoma | terminated | Phase 2 | 8 | Molecular Templates, Inc.INDUSTRY | 1 | Aug 16, 2022 | clinicaltrials |
| NCT03645395 | Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Multiple Dose Regimens of MT-3724 With Lenalidomide for the Treatment of Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (MT-3724_NHL_003) | terminated | Phase 2 | 9 | Molecular Templates, Inc.INDUSTRY | 1 | Aug 16, 2022 | clinicaltrials |
| NCT01464034 | A Safety and Efficacy Study of Carfilzomib and Pomalidomide With Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma | terminated | Phase 1 / Phase 2 | 136 | Criterium, Inc.INDUSTRY | 1 | Aug 1, 2022 | clinicaltrials |
| NCT02793583 | Study to Assess the Efficacy and Safety of Ublituximab + Umbralisib With or Without Bendamustine and Umbralisib Alone in Patients With Previously Treated Non-Hodgkins Lymphoma(UNITY-NHL) | terminated | Phase 2 / Phase 3 | 710 | TG Therapeutics, Inc.INDUSTRY | 9 | Jul 21, 2022 | clinicaltrials |
| NCT03207256 | Extension Trial of Ublituximab and TGR-1202 in Combination or as Single Agents in Subjects Currently Receiving Treatment on Ublituximab and/or TGR-1202 Trials | terminated | Phase 2 | 51 | TG Therapeutics, Inc.INDUSTRY | 1 | Jul 21, 2022 | clinicaltrials |
| NCT00464178 | A Phase II Study of Bevacizumab and Bortezomib in Patients With Relapsed/Refractory Multiple Myeloma | terminated | Phase 2 | 7 | Hackensack Meridian HealthOTHER | 1 | Jul 20, 2022 | clinicaltrials |
| NCT01241786 | Study Examining the Combination of Revlimid (Lenalidomide)and Vidaza (Azacitidine) for Relapsed/Refractory CLL and SLL(VZCLLPI0146) | terminated | Phase 2 | 5 | Hackensack Meridian HealthOTHER | 1 | Jul 20, 2022 | clinicaltrials |
| NCT01555281 | Nelfinavir and Lenalidomide/Dexamethasone in Progressive Multiple Myeloma | terminated | Phase 1 / Phase 2 | 33 | Swiss Cancer InstituteOTHER | 2 | Jul 7, 2022 | clinicaltrials |
| NCT02374424 | Phase II Study With Ga101-DHAP as Induction Therapy in Relapsed/Refractory DLBCL Patients(GIOTTO) | terminated | Phase 2 | 29 | Fondazione Italiana Linfomi - ETSOTHER | 1 | Jun 6, 2022 | clinicaltrials |
| NCT03256045 | Panobinostat, Carfilzomib, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma | terminated | Phase 2 | 9 | University of WashingtonOTHER | 1 | May 9, 2022 | clinicaltrials |
| NCT03303950 | Allogeneic Stem Cell Transplantation for Multiple Myeloma and Myelofibrosis | terminated | Phase 2 | 6 | University of UtahOTHER | 1 | May 5, 2022 | clinicaltrials |
| NCT02043587 | Chemotherapy With Liposomal Cytarabine CNS Prophylaxis for Adult Acute Lymphoblastic Leukemia & Lymphoblastic Lymphoma | terminated | Phase 2 | 31 | University of California, San DiegoOTHER | 1 | May 2, 2022 | clinicaltrials |
| NCT03850522 | PD-L1 Peptide Vaccination in High Risk Smoldering Multiple Myeloma | terminated | Phase 2 | 6 | Lene Meldgaard KnudsenOTHER | 1 | Apr 15, 2022 | clinicaltrials |
| NCT04155840 | Bendamustine and Rituximab in Combination With Copanlisib for the Treatment of Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | terminated | Phase 2 | 1 | University of WashingtonOTHER | 1 | Apr 11, 2022 | clinicaltrials |
| NCT03713320 | SOLAR: Efficacy and Safety of Cobomarsen (MRG-106) vs. Active Comparator in Subjects With Mycosis Fungoides(SOLAR) | terminated | Phase 2 | 37 | miRagen Therapeutics, Inc.INDUSTRY | 8 | Apr 8, 2022 | clinicaltrials |
| NCT02420795 | Akt/ERK Inhibitor ONC201 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma | terminated | Phase 1 / Phase 2 | 16 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 4, 2022 | clinicaltrials |
| NCT03104270 | Combination Study for High Risk Multiple Myeloma Patients | terminated | Phase 2 | 13 | OncotherapeuticsINDUSTRY | 1 | Mar 31, 2022 | clinicaltrials |
| NCT02356458 | Combination of Ibrutinib and Bortezomib to Treat Patients With Mantle Cell Lymphoma | terminated | Phase 1 / Phase 2 | 58 | Swiss Cancer InstituteOTHER | 3 | Mar 11, 2022 | clinicaltrials |
| NCT04209621 | Duvelisib for Ibrutinib-Resistant Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | terminated | Phase 2 | 3 | National Heart, Lung, and Blood Institute (NHLBI)NIH | 1 | Mar 9, 2022 | clinicaltrials |
| NCT01685606 | Study of Infusion of Blood Cells (Lymphocytes) to Stimulate the Immune System to Fight Leukemia/Lymphoma(273) | terminated | Phase 2 | 6 | Brown UniversityOTHER | 1 | Mar 4, 2022 | clinicaltrials |
| NCT04044560 | Blinatumomab for MRD in Pre-B ALL Patients Following Stem Cell Transplant(OZM-097) | terminated | Phase 2 | 8 | University of British ColumbiaOTHER | 1 | Feb 21, 2022 | clinicaltrials |
| NCT00792506 | Phase II Clinical Trial of ITF2357 In Patients With Relapsed/Refractory Multiple Myeloma | terminated | Phase 2 | 1 | ItalfarmacoINDUSTRY | 1 | Feb 2, 2022 | clinicaltrials |
| NCT03875495 | A Phase I/II Study Evaluating Temferon in Multiple Myeloma Patients With Early Relapse After Front Line Therapy (TEM-MM) | terminated | Phase 1 / Phase 2 | 9 | Genenta ScienceINDUSTRY | 1 | Jan 28, 2022 | clinicaltrials |
| NCT00496431 | phII Study of an HDAC Inhibitor in Very High-risk Relapsed/Refractory Hodgkin's Lymphoma Patients | terminated | Phase 1 / Phase 2 | 19 | ItalfarmacoINDUSTRY | 1 | Jan 27, 2022 | clinicaltrials |
| NCT04097301 | Study of CAR T-cell Therapy in Acute Myeloid Leukemia and Multiple Myeloma | terminated | Phase 1 / Phase 2 | 8 | AGC Biologics S.p.A.INDUSTRY | 2 | Jan 19, 2022 | clinicaltrials |
| NCT00476554 | A Randomized Phase II Study of Oral Sapacitabine in Patients With Advanced Cutaneous T-cell Lymphoma | terminated | Phase 2 | 16 | Cyclacel Pharmaceuticals, Inc.INDUSTRY | 1 | Dec 22, 2021 | clinicaltrials |
| NCT03954106 | A Safety and Efficacy Study of Defibrotide in the Prevention of Chimeric Antigen Receptor-T-cell-associated Neurotoxicity | terminated | Phase 2 | 25 | Jazz PharmaceuticalsINDUSTRY | 1 | Dec 9, 2021 | clinicaltrials |
| NCT00479167 | A Phase II Trial of Combined Weekly Bortezomib and Tositumomab I-131 in Patients With Relapsed or Refractory Follicular Non-Hodgkin's Lymphoma | terminated | Phase 2 | 1 | Rush University Medical CenterOTHER | 1 | Nov 4, 2021 | clinicaltrials |
| NCT01585688 | Phase I/II Study of hLL1-DOX in Relapsed NHL and CLL | terminated | Phase 1 / Phase 2 | 13 | Gilead SciencesINDUSTRY | 1 | Oct 8, 2021 | clinicaltrials |
| NCT01468311 | Yttrium-90-labeled Daclizumab With Chemotherapy and Stem Cell Transplant for Hodgkin's Lymphoma | terminated | Phase 1 / Phase 2 | 6 | National Cancer Institute (NCI)NIH | 1 | Oct 6, 2021 | clinicaltrials |
| NCT01549886 | Phase 2 Study of Zevalin Versus Zevalin and Motexafin Gadolinium in Patients With Rituximab-Refractory Low-grade or Follicular B-cell Non-Hodgkin's Lymphoma | terminated | Phase 2 | 5 | Spectrum Pharmaceuticals, IncINDUSTRY | 1 | Oct 4, 2021 | clinicaltrials |
| NCT01045382 | MSC and HSC Coinfusion in Mismatched Minitransplants | terminated | Phase 2 | 39 | University of LiegeOTHER | 1 | Sep 8, 2021 | clinicaltrials |
| NCT01805037 | Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas | terminated | Phase 1 / Phase 2 | 20 | Northwestern UniversityOTHER | 1 | Sep 1, 2021 | clinicaltrials |
| NCT00113802 | Study of Epratuzumab (hLL2) in Patients With Waldenstrom's Macroglobulinemia | terminated | Phase 2 | 31 | Gilead SciencesINDUSTRY | 1 | Aug 19, 2021 | clinicaltrials |
| NCT00490776 | Study of Oral LBH589 in Adult Participants With Refractory/Resistant Cutaneous T-Cell Lymphoma (CTCL) | terminated | Phase 2 | 9 | Novartis PharmaceuticalsINDUSTRY | 1 | Aug 18, 2021 | clinicaltrials |
| NCT01101594 | A Study of hLL1-DOX (Milatuzumab-Doxorubicin Antibody-Drug Conjugate) in Patients With Multiple Myeloma | terminated | Phase 1 / Phase 2 | 17 | Gilead SciencesINDUSTRY | 1 | Aug 16, 2021 | clinicaltrials |
| NCT02489123 | Enzalutamide in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma | terminated | Phase 2 | 8 | University of WashingtonOTHER | 1 | Aug 10, 2021 | clinicaltrials |
| NCT03634800 | Radiotherapy With Immunotherapy for Systemic Effect in Myeloma (RISE-M)(RISE-M) | terminated | Phase 2 | 6 | Weill Medical College of Cornell UniversityOTHER | 1 | Aug 5, 2021 | clinicaltrials |
| NCT01946152 | Pomalidomide, Dexamethasone, and Filgrastim-sndz in Treating Patients With Relapsed or Refractory Multiple Myeloma | terminated | Phase 1 / Phase 2 | 21 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 30, 2021 | clinicaltrials |
Data updated 23 days agoSource updated Nov 8, 2022source: clinicaltrials